Encompass Health (NYSE:EHC) EVP Sells $588,255.22 in Stock

Encompass Health Corporation (NYSE:EHC) EVP John Patrick Darby sold 4,858 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $121.09, for a total value of $588,255.22. Following the transaction, the executive vice president owned 75,041 shares of the company’s stock, valued at $9,086,714.69. This trade represents a 6.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

John Patrick Darby also recently made the following trade(s):

• On Monday, August 10th, John Patrick Darby sold 8,906 shares of Encompass Health stock. The shares were sold at an average price of $125.95, for a total value of $1,121,710.70.

Encompass Health Trading Up 1.3%

NYSE:EHC traded up $1.55 on Tuesday, reaching $121.77. 291,553 shares of the stock traded hands, compared to its average volume of 1,060,619. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 1-year low of $92.77 and a 1-year high of $127.99. The company’s 50 day moving average is $113.64 and its 200-day moving average is $107.27. The firm has a market capitalization of $12.01 billion, a price-to-earnings ratio of 19.83, a price-to-earnings-growth ratio of 2.45 and a beta of 0.72.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the company earned $1.40 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Equities research analysts anticipate that Encompass Health Corporation will post 6.08 EPS for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Thursday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s dividend payout ratio (DPR) is 12.38%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EHC. Transamerica Financial Advisors LLC bought a new stake in shares of Encompass Health during the second quarter valued at approximately $29,000. Persistent Asset Partners Ltd bought a new position in shares of Encompass Health in the 2nd quarter worth $36,000. Keating Financial Advisory Services Inc. acquired a new stake in Encompass Health in the 2nd quarter valued at $39,000. Assetmark Inc. increased its stake in Encompass Health by 89.6% during the 1st quarter. Assetmark Inc. now owns 455 shares of the company’s stock valued at $44,000 after purchasing an additional 215 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in Encompass Health by 36,200.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after purchasing an additional 362 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on EHC shares. Weiss Ratings raised Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Barclays raised their target price on Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. UBS Group boosted their price target on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, August 7th. TD Cowen increased their price target on Encompass Health from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Leerink Partners set a $152.00 price objective on shares of Encompass Health in a research report on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $148.71.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.